Drugs / PSMA-Targeted [In-111]-Labeled Trillium Compound
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05773703 | Dec 2022 → Dec 2023 | prostate cancer | Ratio Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSMA-Targeted [In-111]-Labeled Trillium Compound | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05773703 ↗ |